{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Austria Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/at/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/at/healthcare/feed.json", "description": "Latest Healthcare company headlines from Austria, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "source:396b8943bc130b409a8ca530112b67c8f94c9255480eb1ca6214aedad773fdf9", "url": "https://finance.yahoo.com/healthcare/articles/bofa-biotech-scorecard-two-buys-170700221.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bofa-biotech-scorecard-two-buys-170700221.html", "title": "BofA biotech scorecard: Two buys and odd one out", "content_text": "Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the 13th, where Amgen (AMGN), Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) share a page but leave with very different grades. The note, published Aug. 12, walks through second-half catalysts across BofA's biotech coverage list. Gilead and Vertex both carry Buy ratings, and Vertex is one of the ", "date_published": "2026-08-14T17:07:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VRTX"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VRTX", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/fee7d842-2926-49da-b982-b07badc835ff/"}]}}, {"id": "source:3362a91c187ffecceafb68a55490cb10abf624965e2fb1a9caefbfbd62e12bfa", "url": "https://finance.yahoo.com/healthcare/articles/cvs-sustain-2026-recovery-raising-150100845.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cvs-sustain-2026-recovery-raising-150100845.html", "title": "Can CVS Sustain Its 2026 Recovery After Raising Earnings Guidance?", "content_text": "CVS Health CVS raised its 2026 earnings and cash-flow outlook after a second quarter marked by stronger profitability across all operating segments. The improvement gives the company more room to rebuild margins after a difficult period for its Aetna insurance business. The recovery is gaining traction, but the path is not risk-free. Medical-cost pressure, reimbursement changes and a changing pharmacy benefit manager environment could still test the durability of the higher outlook. CVS Q2 Results Show Broad-Based Improvement Second-quarter adjusted earnings rose 42.5% year over year to $2.58 ", "date_published": "2026-08-14T15:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CVS"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CVS", "name": "CVS Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3238e93c-c07d-4b9b-a89d-cf3bd2ca2f9b/"}]}}, {"id": "source:7aa246a96c2ae38b2c51e74b6231d8e52872b8adde4ca881c01d90c4a25c2bec", "url": "https://finance.yahoo.com/healthcare/articles/cvs-building-consumer-health-care-143900575.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cvs-building-consumer-health-care-143900575.html", "title": "How CVS Is Building on Its Consumer-Health Care Technology Push", "content_text": "CVS Health CVS sees its technology investments as an inflection point as it works to become a more consumer-based health care technology company. Last year, the company committed to invest $20 billion over the next decade in emerging technologies to simplify the health care experience and improve customer engagement. The investment includes developing an open platform that can provide seamless access to payers, providers, pharmacy benefit managers (PBMs), pharmacies and digital health tools. CVS recently began the targeted launch of its Health100 platform, including Haio, an artificial intelli", "date_published": "2026-08-14T14:39:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CVS"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CVS", "name": "CVS Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3238e93c-c07d-4b9b-a89d-cf3bd2ca2f9b/"}]}}, {"id": "source:209c7ec5a3bdfb62d9476f6af4aa8804531855d96c1744e17ad789a7b9de2d79", "url": "https://finance.yahoo.com/healthcare/articles/3-large-cap-stocks-watch-135000158.html", "external_url": "https://finance.yahoo.com/healthcare/articles/3-large-cap-stocks-watch-135000158.html", "title": "3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold", "content_text": "The drug and biotechnology sector has had a strong recovery so far in 2026, driven by innovation, robust quarterly performances, optimistic full-year outlooks, positive regulatory updates and a major wave of M&A activity. However, it faces its share of headwinds like slower-than-expected launches of newer therapies, looming patent expirations for several blockbuster drugs and ongoing policy and pricing uncertainty in major markets. Competitive pressure, particularly in fast-growing areas like obesity/cardiometabolicand cancer treatments, also remains intense. Despite these headwinds, the indus", "date_published": "2026-08-14T13:50:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:716db2c758fe7563d890b3fd84cd08700f39c2dc0800cb2ca92c80723134e873", "url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Lantheus gains FDA nod for tau PET imaging agent in Alzheimer\u2019s", "content_text": "[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer\u2019s disease through positron emission tomography (PET). Specifically, the approval allows the use of Tauklarify in cognitively impaired adults who are investigated for Alzheimer\u2019s disease to detect if there is any tau neurofibrillary tangle pathology causing the condition. Patients should undergo diagnostic tests, such as PET scans, to determine t", "date_published": "2026-08-14T12:31:50+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Regulatory and legal", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:feb4c10773207b089470a45f64ed6c862c294f24a43dcb044c603c039d23c4d0", "url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "external_url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "title": "Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains", "content_text": "While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering. Continue Reading", "date_published": "2026-08-14T12:00:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:e6793ea00b43a8209175c2cdffd939d23887d050c43a1a645355d97124e49d99", "url": "https://www.nasdaq.com/articles/fidelity-healthcare-etf-vs-ishares-pharma-fund-which-wins", "external_url": "https://www.nasdaq.com/articles/fidelity-healthcare-etf-vs-ishares-pharma-fund-which-wins", "title": "Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?", "content_text": "Key Points Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.37% fee for iShares U.S. Pharmaceuticals ETF. iShares' fund provides concentrated exposure to 56 pharmaceutical stocks, while Fidelity's holds 338 stocks across the broader healthcare sector. The iShares fund delivered a higher one-year total return of 60% as of Aug. 10, 2026.10 stocks we like better than Fidelity Covington Trust - Fidelity Msci Health Care Index ETF \u203a While Fidelity MSCI Health Care Index ETF(NYSEMKT:FHLC) provides broad healthcare exposure at a very low cost, iShares U.S. P", "date_published": "2026-08-14T11:35:01+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:a70cae582178023f97c17d47a0839120926b87bdd694780e1f452e8d69dbcac0", "url": "https://finance.yahoo.com/healthcare/articles/mark-cuban-says-401-k-111500193.html", "external_url": "https://finance.yahoo.com/healthcare/articles/mark-cuban-says-401-k-111500193.html", "title": "Mark Cuban says your 401(k) is \u2018part of the cost of health care problem.\u2019 Do you dump Big Insurance and own your values?", "content_text": "Photo by Nicola Gell / Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below. If your retirement savings are invested in a broad index fund, Mark Cuban says you may be helping America's largest health insurers put profits ahead of patients. \"If you own shares in a fund that owns any of the biggest insurance carriers, you are part of the cost of health care problem in this country,\" the billionaire entrepreneur wrote on X (1). Must Read Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 \u2014 6 ways to b", "date_published": "2026-08-14T11:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "UNH", "CVS"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "UNH", "name": "UnitedHealth Group Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/1a38f959-2410-4284-989a-697dc884b739/"}, {"symbol": "CVS", "name": "CVS Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3238e93c-c07d-4b9b-a89d-cf3bd2ca2f9b/"}]}}, {"id": "source:cf8f8e2e6dfcace0e6fe8f5af3d77937351bfb2e3ce92051161d225e3ad41307", "url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "external_url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "title": "Envetec Appoints Patrick S. Jones as Independent Director", "content_text": "Envetec Senior Thermo Fisher Scientific executive brings nearly 30 years of healthcare and commercial leadership to support Envetec's global expansion Patrick S. JonesPatrick S. Jones, President of Thermo Fisher Scientific's Clinical Diagnostics Division and independent director of Envetec Sustainable Technologies BIRDHILL, Ireland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Envetec Sustainable Technologies Limited (Envetec), a leading sustainability innovator in clean technology for healthcare and life sciences, today announced the appointment of Patrick S. Jones, president of Thermo Fisher Scientific", "date_published": "2026-08-14T07:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:7c89340fa6041bf9ee98102a217dbed4be3be36a863f3dd727800eb04c101d76", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPQlJWQzk0bENuazV5bGJZT0ExT0pBdHhpMEFETGl3QnEtZk40bFVsc0U0dzdIakVnTFNVclEtMXFLMGJwUlptM3Nha1hpMmdOLTdYNG1yRVFvV0JwU2VQWlV4cmJEQjA4dW9zby1uTFNYZXF4QXhUN3lUOFJkalQ2UXFuX1F1WGZqMjloSW1oa3NmSEktclhNMnNHbDhqOGJtWnQzLUFaT0lySFQ0b2RCWWRsdnI4cGhzaWZzMmMybkJrVktGbjdzOWZiWndmb05Ick1B?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPQlJWQzk0bENuazV5bGJZT0ExT0pBdHhpMEFETGl3QnEtZk40bFVsc0U0dzdIakVnTFNVclEtMXFLMGJwUlptM3Nha1hpMmdOLTdYNG1yRVFvV0JwU2VQWlV4cmJEQjA4dW9zby1uTFNYZXF4QXhUN3lUOFJkalQ2UXFuX1F1WGZqMjloSW1oa3NmSEktclhNMnNHbDhqOGJtWnQzLUFaT0lySFQ0b2RCWWRsdnI4cGhzaWZzMmMybkJrVktGbjdzOWZiWndmb05Ick1B?oc=5", "title": "Die Fresenius-Aktie steigt nach erh\u00f6hter Prognose und R\u00fcckenwind von UBS", "content_text": "Die Fresenius-Aktie steigt nach erh\u00f6hter Prognose und R\u00fcckenwind von UBS", "date_published": "2026-08-14T06:09:36+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "FRE"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FRE", "name": "Fresenius SE & Co. KGaA", "sentiment_url": "https://sharemaestro.com/sentiment/3b667976-48d7-418d-8c95-72e108b7f5d0/"}]}}, {"id": "source:cafe33c7ee73f6b984147b313061d92fcd1333eadfcaa3189464866c61cca1ba", "url": "https://finance.yahoo.com/markets/stocks/articles/5-revealing-analyst-questions-eli-054900384.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/5-revealing-analyst-questions-eli-054900384.html", "title": "5 Revealing Analyst Questions From Eli Lilly\u2019s Q2 Earnings Call", "content_text": "5 Revealing Analyst Questions From Eli Lilly's Q2 Earnings Call Eli Lilly's second quarter was marked by a positive market reaction, despite the company missing Wall Street's revenue expectations. Management credited growth in key products\u2014especially in cardiometabolic health, oncology, and neuroscience\u2014as drivers of performance. CEO David Ricks pointed to \"robust revenue growth across all Key Products and major geographies,\" noting the strength of new medicines and expansion in emerging markets. The launch of Foundayo in the U.S. and UAE, along with ongoing investments in manufacturing and R&", "date_published": "2026-08-14T05:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:0900c281a1b7e54999dfd196bbfe90a2a2a5cb52fdbe999e1d2a91793c625390", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "title": "Pfizer and Valneva\u2019s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency", "content_text": "Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR \"Vaccine Ag", "date_published": "2026-08-14T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:6d07e1170c1c7e05d704e304386b7fd0cec05076d2d3b1dd36866710208c5f2d", "url": "https://finance.yahoo.com/healthcare/articles/cvs-health-cvs-rolls-pbm-031718282.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cvs-health-cvs-rolls-pbm-031718282.html", "title": "CVS Health (CVS) Rolls Out New PBM Tools As Employer Trust Grows", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. CVS Health (NYSE:CVS) reports that employers show higher trust in pharmacy benefit managers to manage drug costs and access to complex treatments, according to a new CVS Caremark survey. The company is rolling out new digital tools for its PBM clients to manage pharmacy benefits and monitor prescription spending. CVS is expanding coverage for biosimilars and GLP-1 therapies across its pharmacy network with a focus on afforda", "date_published": "2026-08-14T03:17:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CVS"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CVS", "name": "CVS Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3238e93c-c07d-4b9b-a89d-cf3bd2ca2f9b/"}]}}, {"id": "source:350e8b0f908a191d1ec65427f675fa0c0434ffe64637da431ccf76d5a5533ef2", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-syk-still-look-undervalued-031601632.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-syk-still-look-undervalued-031601632.html", "title": "Can Stryker (SYK) Still Look Undervalued After Backlog Recovery?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Str", "date_published": "2026-08-14T03:16:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:fe57a5427a6ee73cd86c5d8745e1445ab11aaa91307d49536ddca77ccfc1bd5d", "url": "https://finance.yahoo.com/markets/stocks/articles/top-5-analyst-questions-cvs-030900470.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/top-5-analyst-questions-cvs-030900470.html", "title": "The Top 5 Analyst Questions From CVS Health\u2019s Q2 Earnings Call", "content_text": "The Top 5 Analyst Questions From CVS Health's Q2 Earnings Call CVS Health's second quarter was marked by better-than-expected revenue and profit, but investor sentiment was dampened by rising concerns over sustainability of these results. Management cited strong performance across all business segments, particularly from specialty pharmacy and Medicare Advantage, as key drivers. CEO David Joyner acknowledged, \"the cumulative impact of these actions [in Aetna and Caremark] is starting to come through clearly in our results.\" However, management also highlighted pockets of pressure, such as ongo", "date_published": "2026-08-14T03:09:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CVS"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CVS", "name": "CVS Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3238e93c-c07d-4b9b-a89d-cf3bd2ca2f9b/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ABBV"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/08efad69-cb19-4d91-96ec-5ca4e3b9d43e/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/5cb5b173-9404-403f-96e5-f1e000f3ec40/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:0cf9b0bafc74581624313018706925e5b7ffbaa1f8371efffb9791a217b0b884", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "title": "Could AbbVie Inc. (ABBV)\u2019s Post-Humira Transformation Drive the Next Phase of Growth?", "content_text": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08\u2013$14.28. Adding to its commercial trajectory, AbbVie's Allergan Aesthe", "date_published": "2026-08-13T21:33:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/08efad69-cb19-4d91-96ec-5ca4e3b9d43e/"}]}}, {"id": "source:b86a19034e00afa9d2e6cf46ad3ac437d2c17839da92b496fd0c18240c6c4e29", "url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "external_url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "title": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS\u2122, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse", "content_text": "Product Image (Photo: Bristol Myers Squibb)ZENBEXUS\u2122 (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb's targeted protein degradation platform PRINCETON, N.J., August 13, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has a", "date_published": "2026-08-13T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMYS"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMYS", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/f6173bbe-95b7-4b6d-a943-9a5f9b3dfe02/"}]}}, {"id": "source:06c9383a28c831d166e244315bed34ee2122d4e28940a6a805108264a483d25b", "url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "title": "Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck's pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the F", "date_published": "2026-08-13T20:07:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0211e6e8-c5d1-4887-83fc-5f88917de5ec/"}]}}, {"id": "source:364eedca97d998b6f754e2e7ebee016c2c8b9301ab4ad1d1bea0c30e18b20027", "url": "https://finance.yahoo.com/healthcare/articles/vivani-medical-reports-second-quarter-200500168.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vivani-medical-reports-second-quarter-200500168.html", "title": "Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update", "content_text": "Vivani Medical, Inc. All participants successfully dosed in SLIM-1\u2122, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal\u2122 technology Completion of the Cortigent-ClearOne merger into Cortigent Holdings and initiation of trading on the Nasdaq exchange under ticker symbol CRGT anticipated in the third quarter of 2026 ALAMEDA, Calif., Aug. 13, 2026 (GLOBE NE", "date_published": "2026-08-13T20:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:0307dd02aa0975f7f8405c50db19c72c2cdf264792b461807601c006f7de5fed", "url": "https://finance.yahoo.com/healthcare/articles/assembly-biosciences-reports-second-quarter-200000615.html", "external_url": "https://finance.yahoo.com/healthcare/articles/assembly-biosciences-reports-second-quarter-200000615.html", "title": "Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates", "content_text": "Assembly Biosciences, Inc. \u2013 Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) \u2013 \u2013 Completed $115 million gross financing to support advancement of pipeline programs through key development milestones \u2013 \u2013 GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 \u2013 \u2013 Cash runway projected into 2029, including first $75 million Gilead collaboration extension payment due in Q4 2026 \u2013 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE", "date_published": "2026-08-13T20:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:75945c1d5efeb098163b135d5abb4ce99219477d7736af6fc2e6f09753d896bb", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "title": "Zoetis Receives Emergency Use Authorization for Simparica Trio\u00ae (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies", "content_text": "Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia", "date_published": "2026-08-13T19:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZOTS"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/906ac168-9b6d-475e-9b73-3964f83d88a9/"}]}}, {"id": "source:0f4f9816ac288bbbdb5a400fe337aa24cdb4d2657cfc0feb0472fa5db9f39220", "url": "https://finance.yahoo.com/healthcare/articles/gene-therapy-remains-top-mind-185900886.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gene-therapy-remains-top-mind-185900886.html", "title": "Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success", "content_text": "Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene therapy, while Spherix patient research reveals continued interest in the modality. Exton, PA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The hemophilia gene therapy market is contracting commercially, but physician and patient interest in the modality has not disappeared. Recent commercial developments, including the discontinuation of BEQVEZ\u00ae (Pfizer), withdrawal of ROCTAVIAN\u00ae (BioMarin), and supply challenges for HEMGENIX\u00ae (CSL Behring), have narrowed the available gene ", "date_published": "2026-08-13T18:59:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment", "date_published": "2026-08-13T18:38:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NNO2", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}, {"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:e46340d17e79968c874982ea904781e973354887c194146e1ec14e217f9d295c", "url": "https://finance.yahoo.com/markets/stocks/articles/telstra-stock-slips-1-billion-183752032.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/telstra-stock-slips-1-billion-183752032.html", "title": "Telstra Stock Slips as A$1 Billion Buyback Meets Profit Miss", "content_text": "This article first appeared on GuruFocus. Telstra Group (TLGPY), Australia's largest telecommunications provider, slipped 0.5% in Thursday's early Australian trading. The market's message was pretty clear: another giant buyback was not enough. Telstra unveiled a fresh A$1 billion repurchase program, but annual attributable profit of A$2.24 billion came in below the A$2.30 billion Visible Alpha consensus cited by Reuters. And this is hardly Telstra's first swing at shrinking the share count. The company only finished a separate A$1.25 billion buyback in June. Warning! GuruFocus has detected 4 W", "date_published": "2026-08-13T18:37:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:352a0f3761594e28dc3c1d362f7b538ee156b891d3026295e72946763c29c5ee", "url": "https://finance.yahoo.com/markets/stocks/articles/syk-worth-buying-growth-improves-174900186.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/syk-worth-buying-growth-improves-174900186.html", "title": "Is SYK Worth Buying as Growth Improves but Execution Risks Persist?", "content_text": "Stryker Corporation SYK presents a growth-versus-execution decision. Second-quarter sales and earnings improved sharply as the company recovered from its first-quarter cybersecurity disruption, while margins expanded and demand remained broad. The case is not risk-free. Cyber remediation costs, vascular supply constraints and acquisition execution still matter. For investors, the question is whether Stryker's improving fundamentals and product pipeline justify adding exposure before those operating issues are fully resolved. SYK's Growth Case Is Stronger Than Its Risk Profile Stryker delivered", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ISRG", "SYK"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}, {"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}]}}, {"id": "source:84980dbc017c4e1caacf816c96701866d11ab80a0313de34674c2e716016b3b7", "url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "title": "Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?", "content_text": "Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}, {"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:5971b49dee342142efd77297a630f9275b5f8928066a404b0980f77284728a39", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "title": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?", "content_text": "Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/50847005-e9bf-41e4-b88d-d60b07e5bc5e/"}, {"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:d2b8070a7f11de2bcc7d266e2f82a94fb7c534645525c7d5d6d1821803b2ad18", "url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "title": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story", "content_text": "West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters because the guidance increase was supported by broad HVP momentum rather than a single product line. Execution risks remain in West Vantage and the SmartDose transition, but the earnings trajectory improved. WST's Q2 Beat Resets 2026 Expectations Adjusted earnings rose", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:a037eecd9aac32645ee2d0d31d4fd7f24611ea1ba15b64b64008f2e6918df676", "url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "title": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?", "content_text": "West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above industry levels. WST's growth drivers remain attractive, but the premium multiple leaves less room for operational missteps. WST's HVP Growth Supports the Bull Case HVP Components generated $424.1 million in second-quarter sales, or 49% of total company revenues, and grew 18.4% organic", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:9d26d0c671e6b52bc88015349553cd3b7d1b648cb07b94a61c041492b2d92917", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-escalates-weight-loss-173227558.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-escalates-weight-loss-173227558.html", "title": "Novo Nordisk Escalates Weight-Loss War With Eli Lilly", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead in the U.S. obesity-drug market, raising the stakes for Novo as it tries to narrow the efficacy gap consumers may perceive between Wegovy and Zepbound. Is LLY fairly valued? Test your thesis with our free DCF calculator. Novo Nordisk develops treatments for diabetes, obesity and other chronic disea", "date_published": "2026-08-13T17:32:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:b40ec17efd7608a9b538f7a45f663802bba7284e20cc8d0232feee1d3f8ceb2d", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "title": "Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?", "content_text": "Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley ", "date_published": "2026-08-13T17:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NNO2", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}, {"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:9ffe2c00b2a37cdcea4a80a976a9d7e6f8e3a809762571c555c7e62d96d599f7", "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "title": "Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the cheap side rather than pointing to an obvious premium. With that backdrop, investors are weighing whether the recent share price around US$135.87 already reflects the key drivers that have supported the move. A 126.6% return over 5 years suggests Gilead Sciences has rewarded long term holders, so the question is how much of ", "date_published": "2026-08-13T17:11:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:fa1625d52811a8c2cdf68e6ccbcfdc979c1b312f424d65b9933a6954890be256", "url": "https://finance.yahoo.com/markets/stocks/articles/sanofi-information-concerning-total-number-163400000.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/sanofi-information-concerning-total-number-163400000.html", "title": "Sanofi: Information concerning the total number of voting rights and shares - July 2026", "content_text": "Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de l'Autorit\u00e9 des March\u00e9s Financiers (Regulation of the French stock market authority) Sanofi a French soci\u00e9t\u00e9 anonyme with a registered share capital of \u20ac2,415,546,786 Registered office : 46, avenue de la Grande Arm\u00e9e - 75017 Paris - France Registered at the Paris Commercial and Companies Registry under number 395 030 844 Date Total number of issued shares Number ", "date_published": "2026-08-13T16:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "SANO"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SANO", "name": "Sanofi", "sentiment_url": "https://sharemaestro.com/sentiment/9c151d33-065a-46d2-a1ff-c7ea6b847ee0/"}]}}, {"id": "source:5a0d5b0118aed9417b7f16d5981c04f347cdcc4923eab2e106061425e0ed31a4", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-stocks-close-mixed-thursday-155457527.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-stocks-close-mixed-thursday-155457527.html", "title": "European Stocks Close Mixed in Thursday Trading; UK GDP Growth Slows in Q2", "content_text": "The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-13T15:54:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:099661ecc0bba4c15ccaa35c84a4fa3d5949068502d3e0f1d3319564d315019c", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-rise-151440591.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-rise-151440591.html", "title": "European Equities Traded in the US Rise in Thursday Trading", "content_text": "European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.45% to 1,969.72 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-13T15:14:40+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:33e32a55454fb0399fcd532ed23175ffd075d37280d0c841a24aff8a18065e15", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "title": "How Pfizer\u2019s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story", "content_text": "In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50\u2013US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer's autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology and dermatology pipeline. We'll now explore how Pfizer's higher 2026 revenue guidance, backed by non-COV", "date_published": "2026-08-13T15:12:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}]}}, {"id": "source:ec826990d2c6b2707cb2345a499149ef75cc010896670e707947cc069f7f222f", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "title": "Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an", "date_published": "2026-08-13T15:12:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:21cdd6efb4f006a77a1ccec8b3e58b1a3934172bb51c9e54a5a601ca9f190457", "url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "external_url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "title": "The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists", "content_text": "NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing. For more than 30 years, the ARF David Ogilvy Awards have recognized campaigns that demonstrate how consumer insights and research can inspire creative work that delivers measurable business results. This year's finalists represent leading brands across categories including Automotive, B2B, Cultural Fluency, Financial Services & Insurance, Food & Beverage, Health & Personal Care, Be", "date_published": "2026-08-13T15:02:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE", "CVS"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d38e875-5b6e-4520-a422-46060912e64a/"}, {"symbol": "CVS", "name": "CVS Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3238e93c-c07d-4b9b-a89d-cf3bd2ca2f9b/"}]}}, {"id": "source:1bf83bc90c892913c96d9159dc11f2436f52e3155ab02f2e8fc6269a170353e1", "url": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "external_url": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "title": "Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD", "content_text": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $156.7 million dollar outflow -- that's a 0.4% decrease week over week (from 506,050,000 to 503,950,000). Among the largest underlying components of TQQQ, in trading today Analog Devices Inc (Symbol: ADI) is up about 0.8%, Marvell Technology Inc (Symbol: MRVL) is up about 4.9%, and Gilead Sciences Inc (Symbol: GILD) is up by about 1%. For a complete list of holdings, visit the TQQQ Holdings ", "date_published": "2026-08-13T14:49:26+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "GILD"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4671d9b0-cfe6-4289-a9c5-3334d8b946be/"}]}}, {"id": "source:db71b0b296aedbce1995a29b5568dcd4026f0c736ce1e90097a67b9907424050", "url": "https://finance.yahoo.com/healthcare/articles/cvs-health-enhances-direct-consumer-143000440.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cvs-health-enhances-direct-consumer-143000440.html", "title": "CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications", "content_text": "WOONSOCKET, RI / ACCESS Newswire / August 13, 2026 / Originally published on CVS Health Company Newsroom CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy through the CVS Health app MinuteClinic digital weight loss visits lowered to $29, the most affordable option in the market, available 24/7 Combines an online visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and ", "date_published": "2026-08-13T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "CVS"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "CVS", "name": "CVS Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3238e93c-c07d-4b9b-a89d-cf3bd2ca2f9b/"}]}}, {"id": "source:285cd116450d19c84ebc238b53aebf9d2f68170dd87757a5fed39d74f6c4c85b", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-glp-1-pill-142600733.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-glp-1-pill-142600733.html", "title": "Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?", "content_text": "Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite NVO delivering a better-than-expected second-quarter 2026 performance. NVO's reported second-quarter sales rose 3% to $12.21 billion (DKK 78.5 billion) at constant exchange rates (CER). More importantly, its key GLP-1 brands showed signs of slowing. Ozempic generated $4.88 billion (DKK 31.4 billion) in repo", "date_published": "2026-08-13T14:26:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}, {"id": "source:8731f7effa586440d1d4919b715b969e8607c86f0ca67737b1e8547b3489afb6", "url": "https://seekingalpha.com/news/4632398-unitedhealth-faces-shareholder-suit-accusing-corporate-governance-failures?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632398-unitedhealth-faces-shareholder-suit-accusing-corporate-governance-failures?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "UnitedHealth faces shareholder suit accusing corporate governance failures", "content_text": "[UnitedHealthcare headquarters in Minnetonka, Minnesota, USA] JHVEPhoto/iStock Editorial via Getty Images UnitedHealth Group (UNH [https://seekingalpha.com/symbol/UNH]) is facing an amended shareholder lawsuit that accuses the insurer of knowing about serious governance issues and doing little to ensure compliance, leading to significant losses in stock value. The suit was filed in a Minnesota federal court by the Employees\u2019 Retirement System of the State of Rhode Island and L\u00e4nsf\u00f6rs\u00e4kringar Fondf\u00f6rvaltning AB, a Swedish asset manager. Plaintiffs blame the board and senior company officers. \"O", "date_published": "2026-08-13T14:18:07+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Capital return", "UNH"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UNH", "name": "UnitedHealth Group Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/1a38f959-2410-4284-989a-697dc884b739/"}]}}, {"id": "source:9d32db924ee34a6fd0c1a4bad9032b1acac67011e96847aee0aa81afd2b0fc08", "url": "https://finance.yahoo.com/healthcare/articles/humana-improve-caregiver-retention-healthstream-141700367.html", "external_url": "https://finance.yahoo.com/healthcare/articles/humana-improve-caregiver-retention-healthstream-141700367.html", "title": "Can Humana Improve Caregiver Retention With HealthStream Deal?", "content_text": "Humana Inc.'s HUM Medicaid managed care plan, Humana Healthy Horizons, is teaming up with HealthStream in Indiana to strengthen the state's home-care workforce. Under the initiative, Humana is sponsoring 1,000 Home Health Aide scholarships, helping remove financial barriers for people entering the caregiving field. The program uses HealthStream's Career Network to reach rural and underserved communities, where worker shortages can restrict access to home-based care. Humana is also deploying HealthStream's CoachUp Care platform, predictive analytics and training tools to help providers recruit ", "date_published": "2026-08-13T14:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "UNH"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "UNH", "name": "UnitedHealth Group Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/1a38f959-2410-4284-989a-697dc884b739/"}]}}, {"id": "source:da0297559d651677418fbbf2281dc586889c01c0c9a0ba40b54c6abb3d366400", "url": "https://finance.yahoo.com/markets/stocks/articles/2-p-500-stocks-exciting-140500822.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/2-p-500-stocks-exciting-140500822.html", "title": "2 S&P 500 Stocks with Exciting Potential and 1 We Ignore", "content_text": "2 S&P 500 Stocks with Exciting Potential and 1 We Ignore The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition. Picking the right S&P 500 stocks requires more than just buying big names, and that's where StockStory comes in. That said, here are two S&P 500 stocks that could deliver good returns and one that may struggle. One Stock to Sell: Hartford (HIG) Market Cap: $38.23", "date_published": "2026-08-13T14:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}]}}, {"id": "source:101ca26192ab6e98d81cd342a73465bb4ea3b94c3cf4262e0826f541a1f35522", "url": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "external_url": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "title": "Can Keytruda Sustain Merck's Growth in the Second Half of 2026?", "content_text": "Merck's MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company's total pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 tumor types, along with two tumor-agnostic approvals as well as for many of these indications worldwide. Notably, more than 2,800 clinical studies are currently evaluating Keytruda across multiple cancer types and treatment settings. Keytruda, approved for several types of cancers, has played an instrumental role ", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ROGH"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ROGH", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/dcb04c87-d9c1-4862-a5fb-05554dd11be7/"}]}}, {"id": "source:f3fab633d584d08932a2870ce562c4f22cbee989985bd7c4a16774be1769ba11", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "title": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation", "content_text": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut", "date_published": "2026-08-13T13:52:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "BIIB"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BIIB", "name": "Biogen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d8a518cd-faae-411d-9e51-ae691d378355/"}]}}, {"id": "source:680781d62dcbd5eeeeb19a08182cf19c2622f9db2db673e90b75e3356e08f20a", "url": "https://finance.yahoo.com/healthcare/articles/llys-foundayo-posts-98m-q2-134200240.html", "external_url": "https://finance.yahoo.com/healthcare/articles/llys-foundayo-posts-98m-q2-134200240.html", "title": "LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?", "content_text": "Eli Lilly and Company LLY announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly's new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April. Foundayo (orforglipron) generated $98 million in sales in the second quarter, its first full quarter on the market. Lilly expects Foundayo to be a commercial game-changer for the company as oral pills are expected to be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Lilly's Ze", "date_published": "2026-08-13T13:42:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLYC", "NNO2"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLYC", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/445698db-0930-4e3d-97d8-e06e548856f7/"}, {"symbol": "NNO2", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fcb49788-2486-40a0-adc0-252e820a9044/"}]}}]}